Keratinocyte growth factor

Bibliography

• Wardley AM, Jason GC, Swindell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000;110:292-99
   PubMed Web of Science ®Google Scholar
• Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem cell transplantation. J Clin Oncol 2001;19:2201-05
   PubMed Web of Science ®Google Scholar
• Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004;4:277-84
   PubMed Web of Science ®Google Scholar
• Denham JW, Hauer-Jensen M. The radiotherapeutic injury–a complex wound. Radiother Oncol 2002;63:129-45
   PubMed Web of Science ®Google Scholar
• Criswell T, Leskov K, Miyamoto S, et al. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003;22:5813-27
   PubMed Web of Science ®Google Scholar
• Sonis ST. The biologic role of nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with antineoplastic therapy. Crit Rev Oral Biol Med 2002;13:300-09
   Google Scholar
• Bamba S, Andoh A, Yasui H, et al. Matrix metalloproteinase 3 secretion from human colonic subepithelial myefibroblasts: role of interleukin 17. J Gastroenterol 2003;38:548-54
   PubMed Web of Science ®Google Scholar
• Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-52
   PubMed Web of Science ®Google Scholar
• Engels-Deutch MA, Pini A, Yamashita Y, et al. Insertional inactivation of pac and rmlB genes reduces the release of tumor necrosis factor alpha, interleukin-6 and interleukin-8 by Streptococcus mutans in monocytic dental pulp and periodontal ligament cells. Infect Immun 2003;71:5169-77
   PubMed Web of Science ®Google Scholar
• World Health Organization: a handbook for reporting results of cancer treatment. Geneva, Switzerland, World Health Organization 1979
   Google Scholar
• Woo S, Sonis ST, Monopoli MM, et al. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer 1993;72:1612-17
   PubMed Web of Science ®Google Scholar
• Finch PW, Rubin JS. Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res 2004;91:69-136
   PubMed Web of Science ®Google Scholar
• Amgen product information for Palifermin. Available from: http://www.kepivance.com [Last accessed on 22 April 2009]
   Google Scholar
• Spencer A, Horvath N, Gibson J, et al. Prospective randomized trial of amifostine cytoprotection in myeloma patients undergoing high dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005;35:971-7
   PubMed Web of Science ®Google Scholar
• Moroni E, Dell'Era P, Rusnati M, Presta M. Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. J Hematother Stem Cell Res 2002;11:19-32
   PubMedGoogle Scholar
• Blijlevens N, Sonis T. Palifermin (recombinant keratinocyte growth factor 1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy and radiotherapy induced mucositis. Ann Oncol 2007: 18817-26
   PubMed Web of Science ®Google Scholar
• Farrell CL, Rex KL, Chen JN, et al. The effects of keratinocyte growth factors in preclinical models of mucositis. Cell Prolif 2002;35:78-85
   PubMed Web of Science ®Google Scholar
• Wu KI, Pollack N, Panos RJ et al. Keratinocyte growth factor promotes alveolar epithelial cell DNA repairafter H2O2 exposure. Am J Physiol 1998;275:L780-787
   PubMed Web of Science ®Google Scholar
• Wildhaber BE, Yang H, Teitelbaum DH. Keratinocyte growth factor decreases total parenteral nutrition induced apoptosis in mouse intestinal epithelium via Bcl-2. J Pediatr Surg 2003;38:92-6
   PubMed Web of Science ®Google Scholar
• Bao S, Wang Y, Sweeney P, et al. Keratinocyte growth factor induces Akt kinase activity and inhibits Fas mediated apoptosis in A549 lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005;288:36-42
   PubMed Web of Science ®Google Scholar
• Krijanowski OI, Hill GR, Cooke KR, et al. Keratinocyte growth factor separates graft versus leukemia effects from graft versus host disease. Blood 1999;94:825-31
   PubMed Web of Science ®Google Scholar
• Panoskaltsis-Mortari A, Taylor PA, Rubin JS, et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood 2000;96:4350-56
   PubMed Web of Science ®Google Scholar
• Farrell CL, Bready JV, Rex KL, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998;58:933-39
   PubMed Web of Science ®Google Scholar
• Potten CS, O'Shea JA, Farrell CL, et al. The effects of repeated doses of keratinocyte growth factor on cell proliferation in the cellular hierarchy of the crypts of the murine small intestine. Cell Growth Differ 2001;12:265-75
   PubMedGoogle Scholar
• Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-8
   PubMed Web of Science ®Google Scholar
• Verhagen MPM, Wondergem MJ, Visser O. Palifermin dose should be adjusted to different therapy regimens. Bone Marrow Transplant 2009;43(8):665
   PubMed Web of Science ®Google Scholar
• Gibson RA, Bowen JM, Keefe DMK. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 2005;116:464-70
   PubMed Web of Science ®Google Scholar
• Dorr W, Bassler S, Reichel S, Spekl K. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): Experimental studies in mice. Int J Radiat Oncol Biol Phys 2005;62(3):881-7
   PubMed Web of Science ®Google Scholar
• Dorr W, Heider K, Spekl K. Reduction of oral mucositis by palifermin (rHuKGF): Dose effect of rHuKGF. Int J Radiat Biol 2005;81:557-65
   PubMed Web of Science ®Google Scholar
• Gibson RJ, Keefe DMK, Clarke JM, et al. The effect of keratinocyte growth factor on tumor growth and small intestinal mucositis after chemotherapy in the rat with breast cancer. Cancer Chemother Pharmacol 2002;50:53-8
   PubMed Web of Science ®Google Scholar
• Ning S, Shui C, Khan WB, et al. Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys 1998;40:177-87
   PubMed Web of Science ®Google Scholar
• Hille A, Rave-Frank M, Pradier O, et al. Effect of keratinocyte growth factor on the proliferation, clonogenic capacity and colony size of human epithelial tumour cells in vitro. Int J Radiat Biol 2003;79:119-28
   PubMed Web of Science ®Google Scholar
• Meropol NJ, Somer RA, Gutheil J, et al. Randomized Phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: Potential role as mucosal protectant. J Clin Oncol 2003;21:1452-58
   PubMed Web of Science ®Google Scholar
• Brizel DM, Murphy BA, Rosenthal DI, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008;26:2489-96
   PubMed Web of Science ®Google Scholar
• Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006;24:5194-200
   PubMed Web of Science ®Google Scholar
• Durrant S, Pico JL, Schultz N, et al. A Phase I study of recombinant keratinocyte growth factor (rHuKGF) in lymphoma patients receiving high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation [abstract]. Blood 1999;94(Suppl 1):708a
   Google Scholar
• Spielberger R, Stiff P, Emmanouilides C, et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in Reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning – results of a phase 2 trial [abstract 25]. Proc Am Soc Clin Oncol 2001;20
   Google Scholar
• Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 2006;24:5186-93
   PubMed Web of Science ®Google Scholar
• Krijanovski OI, Hill GR, Cooke KR, et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999;94:825-31
   PubMed Web of Science ®Google Scholar
• Reynolds CM, Levine JE, Uberti JP, et al. Keratinocyte growth factor (palifermin) in combination with tacrolimus and methotrexate for the prevention of acute graft-vs-host disease (aGVHD) in patients with high risk of aGVHD [abstract 1228]. ASH Annual Meeting Abstracts. Blood 2004;104(11)
   Google Scholar
• Rossi S, Blazer BR, Farrell CL, et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood 2002;100:682-91
   PubMed Web of Science ®Google Scholar
• Blazer BR, Weisdorf DJ, Defor T, et al. Phase 1/ 2 randomized placebo controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006;108:3216-22
   PubMed Web of Science ®Google Scholar
• Nasilowska-Adamska B, Rzepecki P, Manko J, et al. The influence of palifermin (kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplantation 2007;40:983-8
   PubMed Web of Science ®Google Scholar
• Langner S, Staber PB, Schub N, et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem cell transplant recipients. Bone Marrow Transplantation 2008;42:275-79
   PubMed Web of Science ®Google Scholar
• van der Valden WJFM, Herbers AHE, Blijlevens NMA. Palifermin in allogeneic HSCT: many questions remain. Bone Marrow Transplantation 2009;43:85-6
   PubMed Web of Science ®Google Scholar
• Freytes CO, Ratanatharathorn Y, Taylor C, et al. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplant. Clin Cancer Res 2004;10:8318-24
   PubMed Web of Science ®Google Scholar
• A randomized, Phase III, double-blind, placebo-controlled study to evaluate the efficacy and safety of palifermin for the reduction of oral mucositis in patients with locally advanced head and neck cancer receiving radiation therapy with concurrent chemotherapy/ NCT00360971. Available from: http://www.clinicaltrials.gov [Last accessed 22 April 2009]
   Google Scholar
• Phase I/II trial of keratinocyte growth factor to prevent acute GVHD in 6/6 HLA matched BMT recipients/ NCT00031148. Available from: http://www.clinicaltrials.gov [Last accessed 22 April 2009]
   Google Scholar
• A Phase 1 dose-escalation study to evaluate the safety and pharmacokinetics (pk) of Palifermin in pediatric subjects with acute leukemias undergoing myeloablative therapy and allogeneic hematopoietic stem cell transplant (HSCT)/ NCT00460421. Available from: http://www.clinicaltrials.gov [Last accessed 22 April 2009]
   Google Scholar
• A Phase II Trial of Busulfan, Melphalan, and Fludarabine With Peri-Transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)/ NCT00629798. Available from: http://www.clinicaltrials.gov [Last accessed 22 April 2009]
   Google Scholar